JP7776258B2 - ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態 - Google Patents

３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態

Info

Publication number
JP7776258B2
JP7776258B2 JP2020521319A JP2020521319A JP7776258B2 JP 7776258 B2 JP7776258 B2 JP 7776258B2 JP 2020521319 A JP2020521319 A JP 2020521319A JP 2020521319 A JP2020521319 A JP 2020521319A JP 7776258 B2 JP7776258 B2 JP 7776258B2
Authority
JP
Japan
Prior art keywords
cancer
ing
degrees
indol
crystals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020521319A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536944A (ja
JP2020536944A5 (https=
JPWO2019079299A5 (https=
Inventor
チャン、ヤミン
Original Assignee
アクチュエイト セラピューティクス インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクチュエイト セラピューティクス インク． filed Critical アクチュエイト セラピューティクス インク．
Publication of JP2020536944A publication Critical patent/JP2020536944A/ja
Priority to JP2023151499A priority Critical patent/JP2024001040A/ja
Publication of JP2020536944A5 publication Critical patent/JP2020536944A5/ja
Publication of JPWO2019079299A5 publication Critical patent/JPWO2019079299A5/ja
Application granted granted Critical
Publication of JP7776258B2 publication Critical patent/JP7776258B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2020521319A 2017-10-16 2018-10-16 ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態 Active JP7776258B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023151499A JP2024001040A (ja) 2017-10-16 2023-09-19 ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762572603P 2017-10-16 2017-10-16
US62/572,603 2017-10-16
PCT/US2018/056083 WO2019079299A1 (en) 2017-10-16 2018-10-16 SOLID FORMS OF 3- (5-FLUOROBENZOFURAN-3-YL) -4- (5-METHYL-5H- [1,3] DIOXOLO [4,5-F] INDOL-7-YL) PYRROLE-2,5-DIONE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023151499A Division JP2024001040A (ja) 2017-10-16 2023-09-19 ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態

Publications (4)

Publication Number Publication Date
JP2020536944A JP2020536944A (ja) 2020-12-17
JP2020536944A5 JP2020536944A5 (https=) 2025-09-10
JPWO2019079299A5 JPWO2019079299A5 (https=) 2025-09-10
JP7776258B2 true JP7776258B2 (ja) 2025-11-26

Family

ID=64110166

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020521319A Active JP7776258B2 (ja) 2017-10-16 2018-10-16 ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態
JP2023151499A Pending JP2024001040A (ja) 2017-10-16 2023-09-19 ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023151499A Pending JP2024001040A (ja) 2017-10-16 2023-09-19 ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態

Country Status (16)

Country Link
US (3) US11407759B2 (https=)
EP (1) EP3697794B1 (https=)
JP (2) JP7776258B2 (https=)
KR (1) KR102891811B1 (https=)
CN (1) CN111315748B (https=)
AU (1) AU2018352384B2 (https=)
CA (1) CA3074037A1 (https=)
DK (1) DK3697794T3 (https=)
ES (1) ES3064009T3 (https=)
FI (1) FI3697794T3 (https=)
IL (1) IL273920B2 (https=)
MX (1) MX2020003431A (https=)
PL (1) PL3697794T3 (https=)
PT (1) PT3697794T (https=)
WO (1) WO2019079299A1 (https=)
ZA (1) ZA202002740B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3697794T3 (pl) * 2017-10-16 2026-04-07 Actuate Therapeutics Inc. Stałe postacie 3-(5-fluorobenzofuran-3-ylo)-4-(5-metylo-5h-[1,3]dioksolo[4,5-f]indol-7-ilo)pirolo-2,5-dionu
WO2019222483A1 (en) * 2018-05-17 2019-11-21 Board Of Regents, The University Of Texas System Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077138A1 (en) 2006-12-19 2008-06-26 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3665176B1 (en) * 2017-08-11 2024-01-24 Actuate Therapeutics Inc. Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
PL3697794T3 (pl) * 2017-10-16 2026-04-07 Actuate Therapeutics Inc. Stałe postacie 3-(5-fluorobenzofuran-3-ylo)-4-(5-metylo-5h-[1,3]dioksolo[4,5-f]indol-7-ilo)pirolo-2,5-dionu

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077138A1 (en) 2006-12-19 2008-06-26 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J.Med.Chem.,(2009),52(7),pp.1853-1863
PHARM TECH JAPAN,(2002),Vol.18,No.10,pp.81-96
平山令明編著、有機化合物結晶作製ハンドブックー原理とノウハウ－、平成２０年７月２５日発行、ｐｐ．１７－２３、３７－４０、４５－５１、５７－６５

Also Published As

Publication number Publication date
JP2020536944A (ja) 2020-12-17
EP3697794B1 (en) 2025-12-24
IL273920A (en) 2020-05-31
MX2020003431A (es) 2020-07-29
PT3697794T (pt) 2026-03-04
PL3697794T3 (pl) 2026-04-07
IL273920B2 (en) 2025-07-01
US12116374B2 (en) 2024-10-15
ZA202002740B (en) 2025-12-17
DK3697794T3 (da) 2026-02-02
JP2024001040A (ja) 2024-01-09
CN111315748B (zh) 2023-06-27
US20200239489A1 (en) 2020-07-30
US11407759B2 (en) 2022-08-09
ES3064009T3 (en) 2026-04-22
AU2018352384A1 (en) 2020-05-21
WO2019079299A1 (en) 2019-04-25
KR20200100615A (ko) 2020-08-26
EP3697794A1 (en) 2020-08-26
US20250115615A1 (en) 2025-04-10
CN111315748A (zh) 2020-06-19
IL273920B1 (en) 2025-03-01
CA3074037A1 (en) 2019-04-25
KR102891811B1 (ko) 2025-11-28
AU2018352384B2 (en) 2023-12-21
US20220348591A1 (en) 2022-11-03
BR112020007538A2 (pt) 2020-09-24
FI3697794T3 (fi) 2026-02-10

Similar Documents

Publication Publication Date Title
JP7778750B2 (ja) ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態
US20250115615A1 (en) Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
BR112020007538B1 (pt) Forma sólida, processo para preparar a forma sólida, composição farmacêutica, processo para preparar a composição farmacêutica e uso da forma sólida
BR122025019554A2 (pt) Forma sólida de 3-(5-flúor-benzofuran-3-il)-4-(5-metil-5h-[1,3]dioxolo[4,5- f]indol-7-il)pirrol-2,5-diona, seus usos, composição farmacêutica e processo para preparar a mesma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211011

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230919

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230929

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250731

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250827

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251113

R150 Certificate of patent or registration of utility model

Ref document number: 7776258

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150